Compare Amphastar Pharmaceuticals Inc (AMPH) vs Matson Inc (MATX) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

Matson (MATX) trades at $204.77, down 0.61% today but near recent highs, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.85 exceeding expectations. Fundamentals show solid profitability with a 12.92% net income margin and a reasonable P/E of 15.19. Recent developments include a dividend increase to $0.38 per share and progress on new vessel construction.

The outlook remains positive given consistent earnings outperformance and strategic fleet investments, though risks include exposure to Pacific trade volatility and moderating profit margins. Analyst consensus is bullish with 64% buy ratings, supporting potential upside if operational execution continues.